WBB Securities President Dr. Steve Brozak examines five urgent questions emerging from the WHO’s emergency Hantavirus meeting, including transmission risks, global preparedness, and the broader implications for public health systems in a post-pandemic environment.
Read More about 5 Urgent Questions After The WHO Emergency Hantavirus Meeting – Published in ForbesIn a recent Forbes article, Dr. Steve Brozak examines HHS Secretary Robert F. Kennedy Jr.’s focus on the mental health crisis and the growing concern around psychiatric overprescribing.
Read More about Our Mental Health Crisis: RFK Jr. Faces Psychiatric Over-Prescribing – Published in Forbes
WBB Securities President Dr. Steve Brozak moderated a panel at Biotech Showcase 2026 focused on ARPA-H and the role of federal investment in advancing biotech and healthcare innovation. The discussion featured senior ARPA-H leaders and explored how government and industry can work together to accelerate breakthrough science and real-world impact.
Read More about WBB Securities President Dr. Steve Brozak to Moderate ARPA-H Panel at Biotech Showcase 2026 on Federal Investment in Biotech InnovationWBB Securities, LLC has initiated research coverage of Turn Therapeutics, Inc. (NasdaqCM: TTRX), a clinical-stage biotechnology company focused on developing therapies for inflammatory skin and infectious diseases.
Read More about WBB Securities Initiates Coverage of Turn Therapeutics (Nasdaq: TTRX)New insight from WBB Securities President Dr. Steve Brozak in Forbes.
In “The U.S. 2026 Healthcare Cliff: When the Business Model Is the Real Risk,” Steve explores how the potential expiration of enhanced ACA subsidies could expose longstanding structural weaknesses in the U.S. healthcare system, from reimbursement incentives to rising costs and access challenges.
The article highlights why this moment matters for healthcare companies, investors, policymakers, and patients alike.
OYE Therapeutics Raises $5.475 Million Series A to Advance High-Concentration Caffeine Therapy. WBB Securities LLC acted as the placement agent for the Series A financing.
Read More about OYE Therapeutics Raises $5.475 Million Series A to Advance High-Concentration Caffeine Therapy